The Accredo team works closely with you, your physician, your insurance company and your community to provide individualized care that exceeds industry standards.

CareLogic®, our medication and therapy management program, will focus on supporting your physician's care plan as well as on your individual needs. We understand the complexities of bleeding disorder therapy, including the treatment of inhibitors and the extra care required for surgery. We provide each of our bleeding disorder patients with a dedicated team – a group of professionals who work to remove barriers to care and improve clinical outcomes. Our goal is to provide our patients and their families with the knowledge, skills and strategies they need for all aspects of care at every stage of life.

The dedicated, professional Accredo CareLogic team understands each patient's special needs and responds to each case to ensure the best possible outcome. Our successes speak for themselves.

Why choose Accredo? Look at the facts:

The insertion of intravenous (IV) lines is the procedure most frequently associated with the worst pain in children under 5 years of age.1

  • Accredo Nurses have a SINGLE IV attempt rate of 95% in patients 5 years old and under.2

A patient with a bleeding disorder may require a central venous access device (CVAD) due to the frequency of infusions or poor peripheral venous access. CVADs are not without potential risks—catheter infections can occur without meticulous care.

  • Accredo's CVAD infection rate is 33% lower than an industry meta-analysis.3,4 When only Accredo nursing is used, the rate is 97% lower than an industry meta-analysis.5

For children under the age of 6 years, age is a risk factor for a central venous access device (CVAD) infection.3

  • Accredo pediatric patients with a CVAD in place have not shown an increased rate of infection.4

World Federation of Hemophilia (WFH) guidelines indicate that repeated bleeding leads to a progressive decline in joint and muscle function, and to potential disability.6

  • In support of these guidelines, Accredo implemented a patient education program that produced statistically significant results:7
    • 47% drop in the total number of bleeds and 51% drop in joint bleeds
    • 23-34% improvement in joint bleed recognition based on the symptoms
    • 17% increase in use of RICE (rest, ice, compression, elevation)

We value our patients' input and strive for their satisfaction.

  • We are proud of our patient satisfaction rate of 98%.8

For pertinent details and disclosures click here.
1 Cummings EA, Reid GJ, Finley GA, et al. Prevalence and source of pain in pediatric inpatients. Pain. 1996;68:25-31.
2 Accredo data on file 2010.
3 Valentino LA, Ewenstein B, Navickis RJ, et al. Central venous access devices in haemophilia. Haemophilia. 2004;10:134-146.
4 Blankenship CS, Tankersley MA, Johnson N, et al. Central Venous Line Infections in Patients with Hemophilia and Home Care Services. Paper presented at: ISPOR Meeting; May 2010, Atlanta, GA.
5 Accredo data on file 2013.
6 Srivastava A, Brewer AK, Mauser-Bunschoten, et al. Guidelines for the management of haemophilia. Haemophilia (2013),19, e1–e47
7 Blankenship C, Tortella BJ, Bruno M. “Be Empowered,” a novel education program for hemophilia B patients presented by a specialty pharmacy, is associated with a decrease in joint bleeds in adults and an increase in use of RICE in children. In press.
8 December 2012 Accredo patient satisfaction survey data